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HPV infection in the genital tract is common in young sexually active individuals, the majority of whom clear the
infection without overt clinical disease. However most of those who develop benign lesions eventually mount an
effective cell mediated immune (CMI) response and the lesions regress.
Failure to develop effective CMI to clear or control infection results in persistent infection and, in the case of the
oncogenic HPVs, an increased probability of progression to CIN3 and invasive carcinoma. The prolonged duration
of infection associated with HPV seems to be associated with effective evasion of innate immunity thus delaying
the activation of adaptive immunity.
Natural infections in animals show that neutralising antibody to the virus coat protein L1 is protective suggesting
that this would be an effective prophylactic vaccine strategy. The current prophylactic HPV VLP vaccines are
delivered i.m. circumventing the intra-epithelial immune evasion strategies. These vaccines generate high levels of
antibody and both serological and B cell memory as evidenced by persistence of antibody and robust recall
responses. However there is no immune correlate - no antibody level that correlates with protection. Recent data
on how HPV infects basal epithelial cells and how antibody can prevent this provides a mechanistic explanation for
the effectiveness of HPV VLP vaccines.
Introduction
It is chastening to remember that until the mid to late
1970’s - 40 years ago - infection with human papilloma-
viruses was regarded as trivial. The received wisdom
was that HPV caused warts, benign epithelial prolifera-
tions of cutaneous and internal squamous mucosal sur-
faces and nothing more. This view was overset by two
quite disparate reports - one clinical and one, funda-
mental molecular virology. In 1976 Meisels & Fortin
published a report in which they showed that the “halo
cell” in pap smears read by the cytologist was a koilo-
cyte - the pathognomic cell of HPV infection [1]and
that low grade or mild dysplasia of the cervix had the
histological features of a papillomavirus infection [2].
Shortly thereafter Lutz Gissmann in the zur Hausen
laboratory in Erlangen cloned from genital warts ‘condy-
loma acuminata’, a novel HPV DNA classified as HPV6
[3]. Using the DNA sequences from this as a probe Lutz
Gissmann then partially cloned from genital warts
another new HPV - HPV11 [4]. HPV11 DNA was used
by members of the zur Hausen laboratory as a probe
and in 1983 they reported the cloning of a novel HPV
from cervical carcinoma biopsies - HPV16 [5], followed
a year later by another new HPV in cervical carcinoma -
HPV18 [6].
Burden of Disease: high risk or oncogenic HPV strains
Developments since then need little repeating - infection
with one of a subset of mucosal HPVs is the major risk
factor for the development of cervical cancer. There are
at least 15 oncogenic (cancer causing) HPV types or
strains but HPV16 and 18 are the most virulent causing
an average 70% of all cervical cancers [7]. The spectrum
of HPV associated cancers now extends with HPV the
major aetiological agent in squamous cell carcinoma of
the anus, tonsil and base of tongue and a significant
contributor to squamous cell carcinoma of the vulva,
vagina, penis, larynx and head and neck http://globocan.
iarc.fr/ Overall it is estimated that HPV is the causal
agent in 5% of all human cancers with HPV16 by far
and away the major player.
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The contribution to the cancer burden is very significant
but the disease burden of the “benign” or low risk HPVs
- mainly 6 and 11 - should not be underestimated. Gen-
ital warts - condyloma acuminata - are not a preferred
topic of polite conversation but they are the commonest
viral sexually transmitted infection with a life time risk
of acquisition of 10% [8]. This represents a huge disease
burden and major health economic cost in developed
countries. HPV infection in the larynx resulting in
recurrent respiratory papillomatosis is a rare but devas-
tating disease. The juvenile form of this disease - 4/
100,000 live births - results in young infants and chil-
dren with extensive warts in the larynx [9]. These
lesions have to be surgically removed to prevent airway
occlusion and these unfortunate children experience
repeated surgical interventions and the accompanying
anaesthesia to remove the warts. A small fraction of
affected individuals have bronchial and pulmonary
extension that results in mortality [10].
Natural history of HPV infection
HPV infection is determined by detection of DNA, not
isolation of virus. Genital HPV infection is predomi-
nantly, but not exclusively, a sexually transmitted infec-
tion but penetrative vaginal or anal sexual intercourse is
not a prerequisite for infecti o n ,v i r u si st r a n s m i t t e db y
skin to skin contact via intimate contacts of the genitalia
or other mucosal surfaces [11]. These infections are very
common and it is estimated that 50-80% of sexually
active men and women will acquire a genital HPV (both
high and low risk) in their lives. The peak period of
acquisition is soon after the start of sexual activity [12]
and the risk of infection increases with the number of
sexual partners [13].
The natural history of genital HPV infection is illu-
strated in Figure 1. HPV is highly infectious with an
incubation period ranging from 3-4 weeks to months or
years, the duration of this latent period probably relating
to the dose of virus received. Eventually for reasons that
are still not understood permissive viral growth com-
mences, viral DNA can be detected and infectious virus
is shed. This phase of active replication also persists for
a variable length of time but eventually the vast majority
of infected individuals mount an effective immune
response becoming DNA negative with subsequent sus-
tained clinical remission from disease [14]. Effective
immunity consists of a cell mediated response to the
early proteins, principally E2 and E6 [15], necessary for
lesion regression accompanied or followed by sero-con-
version and antibody to the major capsid protein L1.
A minority variously estimated as being between 10-
20% do not effectively clear virus, they remain DNA
positive with a persistent active viral infection and it is
these individuals who are at risk for progression to high
grade precancers in the cervix - cervical intra-epithelial
neoplasia CIN2/3 and thus invasive cancer [11]. HPV
infections are exclusively intra-epithelial; virus infects
basal epithelial cells probably at low copy number and
amplifies in a first round of DNA amplification to 100
or so nuclear episomes per cell. Virus remains in an epi-
some maintenance phase with minimal viral gene
expression in the proliferating compartment of the
epithelium. Viral gene expression becomes maximal in
the differentiating non cycling cells of the upper 1/3 -
2/3 of the epithelium with viral capsid synthesis, assem-
bly and shredding confined to the superficial differen-
tiating squames [16]. This replication strategy with tight
control over early gene expression ensures that in divid-
ing cells the powerful oncogenic properties of the E6/E7
proteins of the high risk HPVs are not allowed to flour-
ish. However, if viral infection becomes persistent then
the probability of molecular accidents deregulating con-
trol of E6/E7 oncogene expression in mitotically active
cells will increase [17] and neoplastic progression starts.
HPV immune evasion strategies
Clearly HPV effectively evades recognition by the
immune system for many months so how does this
occur? The infectious cycle itself is a mechanism for
this - there is no viraemia, very low levels of viral pro-
tein are expressed but crucially HPV is not cytolytic.
Virus replication and assembly occur in cells already
destined for death by anoikis or “death by natural
causes”, there is no inflammation and no danger signal
to alert the immune system. The interferon response for
HPV infection, a key antiviral defence mechanism [18],
is actively suppressed with the E6 and E7 proteins of the
high risk HPVs inhibiting the interferon receptor signal-
ling pathways and the activation of the interferon
response genes [19]. The E7 proteins downregulate
TLR9 [20] and overall HPV effectively evades the innate
immune response delaying the activation of adaptive
immunity.
Prophylactic HPV Vaccines
Humoral response in natural HPV infections
The most effective control of viral infections is prophy-
lactic vaccination and the development of prophylactic
HPV vaccines is one of the scientific triumphs of the
past 20 years. Sero conversion in natural genital infec-
tion results in detectable serum neutralising antibody to
the major capsid protein L1 but this response is slow
with an average time to sero-conversion after the first
detection of HPV16 DNA of 8-9 months, antibody con-
centrations are low and only 50-70% of women
with incident HPV infection sero convert [21]. However,
anti L1 antibody persists in many women for at least
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tive against disease [23]. Neutralising anti L1 antibody was
known to be protective against high dose viral challenge in
the classic animal models of papillomavirus infection, the
dog, cow and rabbit, supporting the notion that a prophy-
lactic HPV vaccine would be effective. Generating such
vaccines was not a trivial issue; papillomaviruses cannot be
grown in bulk in tissue culture so traditional live attenu-
ated or killed vaccines were not feasible. Expression of the
soluble native L1 protein via prokaryotic vectors was gen-
erally unsuccessful however, seminal technical advances in
the early 1990’s showed that if the L1 protein was
expressed via eukaryotic expression systems, assembly into
virus like particles occurred [24,25]. These L1 VLPs were
morphologically and antigenically comparable to wild type
virus and neutralising antibody generated by immunisation
with L1 VLP protected against viral challenge in animal
systems [26,27].
HPV L1 VLP vaccines
There are two licensed HPV L1 VLP prophylactic vac-
cines - Cervarix® a bivalent HPV 16/18 vaccine from
GlaxoSmithKline Biologicals (GSK) and Gardasil®, a
quadrivalent HPV16/18/6/11 vaccine from MSD Merck.
Both vaccines have been shown in randomised control
trials to be highly efficacious against HPV 16/18 caused
high grade cervical intra epithelial disease (CIN2/3) in
15-26 year old women naïve for these HPV types at trial
entry and during the 3 shot immunisation schedule (0, 1
or 2 and 6 months) [28,29]. Additional trial endpoints
were evaluated for the quadrivalent vaccine and high
(>96%) efficacy was shown for HPV6/11/16/18 caused
vulvar and vaginal intra epithelial neoplasia and external
genital warts [30]. In RCTs in 16-23 year old men the
quadrivalent vaccine has been shown to achieve >90%
efficacy against HPV6/11/16/18 caused external genital
warts in heterosexual men and > 73% efficacy against
anal intra-epithelial neoplasia in homosexual men
(Palefsky J personal communication 2010).
There is preliminary evidence for population effective-
ness for the quadrivalent vaccine. In 2008 Australia
offered publicly funded immunisation with the quadriva-
lent vaccine to all women aged 12-26 years and
achieved, overall, 60-70% coverage. Audit of new female
Figure 1 Mechanisms of HPV infection in women genital tract.
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attending a large sexual health clinic in Melbourne,
Australia before and after vaccine introduction showed a
fall in incidence of EGW after vaccine introduction in
this age group of up to 40% Women older than 28 years
who were not in the group eligible for free vaccines
showed no fall in incidence [31].
Mechanisms of HPV vaccine protection
VLP immunogenicity
The current assumption is that the protection afforded
via these vaccines is antibody mediated since passive
immunisation is protective in animal models [26,27].
HPV L1 VLP vaccines are highly immunogenic gener-
ating antibody concentrations after the 3
rd immunisa-
tion that are 1-4 logs higher than those in natural
infections [32,33]. In published studies serum neutra-
lising antibody persists with geometric mean titres
(GMTs) about 1 log greater than natural infection for
the 7-9 year duration of the published studies, [34,35].
Mathematical modelling predicts slow decay of anti-
body over a 30-50 year period and potentially, there-
fore, protection over that time [36,37]. Both type
specific and cross neutralising antibodies are generated
by VLP vaccines although concentrations of cross neu-
tralising species are on average 1-2 logs lower than
type specific [38]. At the present there is no immune
correlate, no antibody concentration (or other immune
measurement) has been defined that correlates with
protection. However other than information on anti-
body concentration (both IgG and neutralising) there
is little published data on other parameters such anti-
body affinity and avidity maturation that may be rele-
vant in this context. Early reports indicate that avidity
maturation does not correlate with antibody concen-
tration or circulating memory B cells [39].
Route of immunisation
The enhanced immunogenicity of VLP immunisation in
contrast to natural infection very probably relates to the
route of immunisation. Natural infection is exclusively
intra epithelial, virus is shed from mucosal surfaces and
there is little or no viraemia. Viral antigen therefore
poorly accesses the lymphatics and draining lymph
nodes (DLN) where immune responses are initiated.
Furthermore the most likely antigen presenting cells
(APC) are macrophages and Langerhans cells both of
which will be relatively ineffective in the non-inflamma-
tory environment of a productive HPV infection (HPV
is not cytolytic). VLP vaccines in contrast are delivered
by injection via the intra-muscular route with immediate
access to the vasculature and lymphatics. They rapidly
encounter stromal dendritic cells that, in the inflamma-
tory milieu induced by vaccination, are strongly
activated to mature and migrate to the DLN initiating
helper T cell responses. At the same time VLPs either
surface bound to APC or other local immunocytes are
shuttled into the lymph node encountering and priming
naïve B cells in the follicle and the whole cascade of
events that will result in protective immunity is started.
Furthermore the VLP is intrinsically very immunogenic.
The exquisite repeat pattern of L1 capsomers that stud
the particle powerfully activate the innate immune sen-
sors [40,41], even in the absence of adjuvant [42], kick
starting the adaptive immune response. These crucial
early events set the pattern for the subsequent immune
cascades.
Immune memory
The antibody response after the 3 dose immunisation
schedule follows the expected pattern. After each vac-
cine dose antibody levels increase until a peak antibody
concentration is achieved one month after the 3
rd and
final dose in the primary schedule. Antibody concentra-
tions wane over the subsequent 12 - 18 months but
then stabilise at a plateau level with GMTs on average
10 times greater than in the placebo groups [32,33].
This pattern is consistent with the notion of the genera-
tion of a large population of antibody secreting plasma
cells after dose 3, with varying life spans but some with
the ability to migrate to the bone marrow surviving as
long lived plasma cells maintaining a low but constant
antibody production [43]. Antigen challenge at
60 months post dose 1 with the quadrivalent vaccine
results in a rapid and robust anamnestic response with
antibody levels rising within 3-5 days to levels greater
than that achieved at peak in the initial immunisation
schedule demonstrating the presence of reactive mem-
ory B cells [44]. A similar pattern of antibody response
is shown by the bivalent vaccine and although there is
no published data on a recall response, antigen specific
circulating memory cells can be detected after each vac-
cine dose peaking after the third immunisation [45].
Collectively these data strongly imply that HPV VLP
immunisation generates both components of the anti-
body memory response ie serological memory and reac-
tive memory [46], a prerequisite for long term vaccine
induced protection.
Mechanism of virus entry
HPVs have an exclusively intra-epithelial life cycle with
either minimal or no viraemia so how can serum neu-
tralising antibody protect against infection? One expla-
nation often offered is that transudated serum antibody
in cervical secretions is the major mechanism of protec-
tion. This must certainly contribute but cannot explain
protection at the well keratinised and comparatively dry
surfaces of the vulva and vagina, penis and peri-anal
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into cells thus the questions to be addressed are how
does HPV access and infect the basal cell of stratified
squamous epithelium and how do neutralising antibo-
dies prevent this. The emerging evidence is that HPV
cell entry is a complex process involving epithelial
microtrauma and wound repair [47]. HPV infects basal
epithelial cells via micro wounds or microabrasions that
remove the full thickness epithelium, but retain the
basement membrane [48]. The virus binds via L1 first to
the basement membrane and then to the cellular recep-
tor on the migrating wound keratinocyte [49]. L1 anti-
bodies can block both of these interactions and those
antibodies that block basement membrane binding neu-
tralise at extremely low concentrations [50]. This pro-
cess of virus entry is slow and current estimates are that
there is a minimum of 12-14 hours before HPV enters
the wound keratinocyte [47] and, since the microwound
will be accompanied by a serous exudate, exposure to
serum antibody will be rapid.
Summary and Conclusions
Infection with an oncogenic HPV particularly HPV 16 is
associated with 5% of all human cancers but predomi-
nantly cervical cancer and other ano-genital cancers.
HPV infection with both oncogenic and non oncogenic
types is common in young, sexually active men and
women but the majority of infections resolve due to a
cell mediated response to early non structural proteins.
This response is usually accompanied by sero-conver-
sion with type specific neutralising antibody to the
major capsid protein L1.
Prophylactic HPV vaccines are sub-unit protein vac-
cines consisting of L1 only virus like particles for HPV
16 and 18 only or HPV 6,11,16 and 18. These VLP vac-
cines are highly immunogenic generating high titres of
type restricted neutralising antibody to L1 and robust
immune memory.
It is generally considered that the >90% protection
afforded by these vaccines against ano-genital disease
associated with the vaccine HPV types is antibody
mediated but at the present there is no immune corre-
late - no measurable antibody titre or other quantifiable
immune response that correlates with protection. How-
ever the mechanism of viral entry may provide insight
into antibody mediated protection. HPV infection of the
epithelial basal cell has been shown to require epithelial
micro-wounding and repair [47-49]. This is a slow,
complex and multi-step process during which virus is
accessible to serum neutralising antibody that enters via
the exudate that accompanies wounding. Experimental
evidence indicates that, at least for HPV 16 very
low (pico-molar) antibody concentrations effectively
neutralise suggesting that very little antibody will be
protective [50].
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